Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
General Internal Medicine
•
Hematology
In patients with AML who achieve a CR with HMA/Ven, what is the optimal dose and schedule for venetoclax for further cycles?
Related Questions
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How does one interpret an SPEP showing potentially obscured but non-quantifiable M-spike however an IFE showing monoclonal protein?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
How do you evaluate a patient with MGUS and peripheral neuropathy?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
What is your approach to treatment of relapsed, high-risk MDS with TP53 mutation in a patient that is not considered a transplant candidate?
